CRBN and Miyoshi myopathy: showed an increased prevalence of mutations in CRBN and CRBN pathway genes (CRBN, CULB4, IRF4, IKZF1) in IMiDs (lenalidomide) refractory patients compared with newly diagnosed MM patients (58).